GO:0016525 negative regulation of angiogenesis: Signaling Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016525 (negative regulation of angiogenesis) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of angiogenesis.
• Endogenous inhibitors such as soluble VEGFR-1 (sFlt-1) sequester VEGF and act as a major brake on blood vessel formation.
• Notch1 signaling, KLF15, and VASN form an endothelial axis that actively suppresses angiogenesis.
• DCBLD1 controls VEGFR-2 endocytosis and thereby modulates angiogenic signaling in endothelial cells.
• Dysregulated negative regulation of angiogenesis contributes to cancer, diabetic foot ulcers, and impaired wound healing.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal roles of anti-angiogenic genes.
Description
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is tightly controlled by a balance of pro- and anti-angiogenic signals. The Gene Ontology term GO:0016525, negative regulation of angiogenesis, captures all processes that stop, prevent, or reduce the frequency, rate, or extent of this vessel-forming program. This term is essential for annotating gene products that act as endogenous inhibitors of angiogenesis, including soluble decoy receptors, signaling pathway suppressors, and extracellular matrix components. Understanding negative regulation of angiogenesis is critical because tipping the balance toward excessive vessel growth drives tumor progression, while excessive inhibition contributes to ischemic and diabetic complications. Researchers studying this term need reliable models to test whether a candidate gene causally suppresses angiogenesis, and CRISPR-based cell models provide that causal link.
negative regulation of angiogenesis At A Glance
| GO ID | GO:0016525 |
|---|---|
| GO term | negative regulation of angiogenesis |
| Ontology | biological_process |
| Synonym | down regulation of angiogenesis, down-regulation of angiogenesis, downregulation of angiogenesis, inhibition of angiogenesis |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of angiogenesis |
| Related processes | VEGF signaling, Notch1 signaling, VEGFR-2 endocytosis, epigenetic regulation |
| Key regulators | sFlt-1 (soluble VEGFR-1), KLF15, VASN, DCBLD1, syndecan-4, Nrf2/HDAC axis |
| Disease relevance | Cancer, diabetic foot ulcers, wound healing, ischemic disease |
What Is GO:0016525?
Negative regulation of angiogenesis (GO:0016525) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of angiogenesis. This includes molecular mechanisms such as sequestration of pro-angiogenic growth factors by soluble receptors, activation of inhibitory signaling cascades in endothelial cells, and epigenetic suppression of pro-angiogenic gene expression. The term is a biological process and is distinct from positive regulation of angiogenesis (GO:0016525 is the negative counterpart).
Why Is negative regulation of angiogenesis Important in Cell Biology?
Negative regulation of angiogenesis is a central homeostatic mechanism that prevents excessive or aberrant blood vessel growth. In cancer, loss of negative regulation allows tumors to become highly vascularized and metastatic, making this process a prime therapeutic target. In diabetes and chronic wounds, impaired negative regulation or excessive inhibition can lead to poor healing or pathological neovascularization. Understanding the molecular players that enforce negative regulation is therefore critical for developing anti-angiogenic therapies and for interpreting endothelial cell biology.
• Controls tumor angiogenesis and metastasis by limiting new vessel formation.
• Regulates vascular normalization and response to anti-angiogenic therapy.
• Modulates wound healing and cutaneous angiogenesis through catecholamines.
• Involved in diabetic foot ulcer progression via epigenetic Nrf2 regulation.
• Mediated by soluble VEGFR-1 (sFlt-1) which acts as a VEGF trap.
• Requires endothelial KLF15/VASN axis and Notch1 signaling.
• Modulated by DCBLD1-dependent VEGFR-2 endocytosis.
• Influenced by syndecan-4 in triple negative breast cancer vasculogenic mimicry.
• Provides targets for anti-angiogenic drug development.
• Essential for understanding vascular homeostasis in health and disease.
What Happens During negative regulation of angiogenesis?
Sequestration of pro-angiogenic growth factors
In simple terms: Decoy receptors soak up VEGF so it cannot activate endothelial cells.
Soluble vascular endothelial growth factor receptor-1 (sFlt-1) acts as a decoy that binds VEGF and PlGF, preventing them from activating VEGFR-2 on endothelial cells, thereby reducing angiogenesis. This sequestration mechanism is a major endogenous negative regulatory pathway.
Activation of inhibitory signaling in endothelial cells
In simple terms: Endothelial cells have built-in brakes like Notch1 that stop them from forming new vessels.
The endothelial KLF15/VASN axis inhibits angiogenesis via activation of Notch1 signaling, demonstrating an active inhibitory signaling cascade within endothelial cells. Notch1 activation downstream of KLF15 and VASN suppresses angiogenic sprouting.
Regulation of receptor endocytosis and turnover
In simple terms: Proteins like DCBLD1 control how many VEGF receptors are on the cell surface, affecting vessel growth.
DCBLD1 modulates angiogenesis by regulating VEGFR-2 endocytosis in endothelial cells, thereby controlling the availability of VEGFR-2 for pro-angiogenic signaling. This endocytic control represents a negative regulatory mechanism that limits angiogenesis.
Epigenetic suppression of pro-angiogenic genes
In simple terms: Histone deacetylases can turn off genes that promote blood vessel growth.
Epigenetic regulation of Nrf2-mediated angiogenesis by histone deacetylases (HDACs) in diabetic foot ulcers demonstrates that negative regulation of angiogenesis can occur through chromatin modification and suppression of pro-angiogenic transcription factors.
Extracellular matrix and proteoglycan modulation
In simple terms: Matrix molecules like syndecan-4 can influence whether new vessels form.
Syndecan-4 plays a role in angiogenesis and vasculogenic mimicry in triple negative breast cancer cells, indicating that extracellular matrix components can negatively or positively modulate angiogenic processes depending on context.
Key Genes Involved in GO:0016525 negative regulation of angiogenesis
The following genes and proteins are experimentally validated participants in negative regulation of angiogenesis (GO:0016525).
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFR1 (FLT1) | Soluble VEGFR-1 (sFlt-1) sequesters VEGF and PlGF, preventing VEGFR-2 activation | Major endogenous negative regulator; target for anti-angiogenic therapy |
| KLF15 | Endothelial transcription factor that activates Notch1 signaling to inhibit angiogenesis | Key inhibitory axis in endothelial cells |
| VASN | Vasorin, part of KLF15/VASN axis that activates Notch1 | Mediates negative regulation of angiogenesis |
| NOTCH1 | Receptor signaling that suppresses angiogenic sprouting | Downstream effector of KLF15/VASN |
| DCBLD1 | Regulates VEGFR-2 endocytosis in endothelial cells | Modulates angiogenesis by controlling receptor availability |
| SDC4 | Syndecan-4, proteoglycan involved in angiogenesis and vasculogenic mimicry | Context-dependent role in triple negative breast cancer |
| Nrf2 (NFE2L2) | Transcription factor regulating antioxidant and angiogenic genes | Epigenetically regulated by HDACs in diabetic foot ulcers |
| HDACs | Histone deacetylases that suppress Nrf2-mediated angiogenesis | Epigenetic negative regulation in diabetic wounds |
| VEGFA | Primary pro-angiogenic growth factor; its sequestration reduces angiogenesis | Target of sFlt-1 and negative regulatory pathways |
| VEGFR2 (KDR) | Main pro-angiogenic receptor; its endocytosis is regulated by DCBLD1 | Central node in negative regulation |
| PIGF | Placental growth factor, binds sFlt-1 | Modulates VEGF signaling |
| Catecholamines | Neurotransmitters that regulate angiogenesis in wound healing | Endogenous modulators of cutaneous angiogenesis |
| HIF1A | Hypoxia-inducible factor, upstream of pro-angiogenic genes | Indirect target of negative regulation |
| TSP1 (THBS1) | Thrombospondin-1, endogenous anti-angiogenic matricellular protein | Classic negative regulator |
| Endostatin | Proteolytic fragment of collagen XVIII with anti-angiogenic activity | Therapeutic anti-angiogenic agent |
| Angiostatin | Plasminogen fragment that inhibits angiogenesis | Endogenous inhibitor |
| VEGFB | VEGF family member with context-dependent effects | Modulates angiogenic balance |
| NRP1 | Neuropilin-1, co-receptor for VEGF | Modulates VEGF signaling and negative regulation |
How Is negative regulation of angiogenesis Regulated?
Negative regulation of angiogenesis is itself regulated at multiple levels. Soluble VEGFR-1 (sFlt-1) levels are controlled by alternative splicing and shedding, directly affecting VEGF bioavailability. The KLF15/VASN axis activates Notch1 signaling, which in turn suppresses pro-angiogenic gene expression. DCBLD1 regulates VEGFR-2 endocytosis, controlling the duration and intensity of pro-angiogenic signaling. Epigenetic mechanisms, including histone deacetylase activity, regulate Nrf2-mediated angiogenesis in diabetic wounds. Catecholamines modulate angiogenesis during cutaneous wound healing, providing neuroendocrine control. These layers of regulation ensure that angiogenesis is tightly balanced under physiological conditions.
negative regulation of angiogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VEGFR1 (FLT1) | Cancer, preeclampsia | Knockout of soluble isoform in endothelial cells; overexpression of sFlt-1 |
| KLF15 | Vascular disorders, cancer | Endothelial-specific knockout and overexpression |
| DCBLD1 | Cancer, angiogenesis | Knockout and point mutation of endocytosis motifs |
| Nrf2 (NFE2L2) | Diabetic foot ulcers | HDAC inhibitor treatment in diabetic wound models |
| SDC4 | Triple negative breast cancer | Knockout in TNBC cell lines; vasculogenic mimicry assays |
Cancer and tumor angiogenesis
In cancer, loss of negative regulation of angiogenesis allows tumors to switch to an angiogenic phenotype, supporting growth and metastasis. Anti-angiogenic therapies aim to restore negative regulation by blocking VEGF or its receptors. Normalization of tumor vasculature through anti-angiogenic strategies can improve drug delivery and reduce metastasis. Soluble VEGFR-1 acts as an endogenous inhibitor that can be exploited therapeutically.
Diabetic foot ulcers and impaired wound healing
In diabetic foot ulcers, epigenetic regulation of Nrf2-mediated angiogenesis by histone deacetylases contributes to impaired wound healing. Excessive or insufficient negative regulation of angiogenesis can lead to poor vascularization and chronic wounds. Catecholamines also regulate angiogenesis in cutaneous wound healing, linking stress to impaired healing.
Triple negative breast cancer and vasculogenic mimicry
Syndecan-4 plays a role in angiogenesis and vasculogenic mimicry in triple negative breast cancer cells, a process where tumor cells form vessel-like structures independent of endothelial cells. This highlights context-dependent negative regulation and potential therapeutic targets.
Vascular normalization and other diseases
Normalization of the vasculature is a therapeutic goal in cancer and other diseases, requiring fine-tuning of negative regulation of angiogenesis. Endothelial KLF15/VASN axis and DCBLD1 represent novel targets for modulating angiogenesis in vascular disorders.
From negative regulation of angiogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X causally inhibit angiogenesis? | CRISPR knockout in endothelial cells followed by tube formation assay |
| Does a specific point mutation in gene X affect its anti-angiogenic function? | CRISPR point mutation knock-in in endothelial cells |
| Does overexpression of gene X suppress tumor angiogenesis? | CRISPR knock-in of a strong promoter or cDNA overexpression |
| Does tagged gene X localize to specific endothelial compartments? | CRISPR knock-in of fluorescent or epitope tag |
| Does gene X regulate VEGFR-2 endocytosis? | Knockout and live-cell imaging of receptor trafficking |
| Does epigenetic modulation of gene X affect angiogenesis in diabetes? | HDAC inhibitor treatment in diabetic wound models |
How to Study the negative regulation of angiogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Test causal role in negative regulation of angiogenesis |
| CRISPR knock-in | Precise mutation or tag insertion | Structure-function and localization studies |
| Tube formation assay | Endothelial cell network formation | Quantify angiogenesis in vitro |
| Western blot | Protein expression and phosphorylation | Measure Notch1, VEGFR-2 signaling |
| Co-immunoprecipitation | Protein-protein interactions | Identify complexes in negative regulation |
| Matrigel plug assay | In vivo angiogenesis | Assess negative regulators in animal models |
| RNA-seq | Transcriptome changes | Identify downstream targets of negative regulators |
| Live-cell imaging | Receptor endocytosis and trafficking | Study DCBLD1-mediated VEGFR-2 endocytosis |
CRISPR knockout and knock-in models
CRISPR-Cas9 knockout of candidate negative regulators in endothelial cells allows causal testing of their role in angiogenesis. Knock-in of point mutations or tags enables precise structure-function studies, such as mapping DCBLD1 domains required for VEGFR-2 endocytosis.
Endothelial cell functional assays
Tube formation, sprouting, and migration assays are standard to measure angiogenesis in vitro after genetic manipulation. These assays quantify the frequency and extent of vessel-like structure formation, directly reflecting negative regulation of angiogenesis.
Molecular signaling analysis
Western blotting, co-immunoprecipitation, and reporter assays measure Notch1 activation, VEGFR-2 phosphorylation, and downstream signaling. These methods reveal how negative regulators intersect with pro-angiogenic pathways.
In vivo angiogenesis models
Matrigel plug assays, corneal micropocket assays, and tumor xenografts assess negative regulation of angiogenesis in vivo. These models are essential for translating in vitro findings to disease contexts.
How CRISPR Can Be Used to Study GO:0016525 negative regulation of angiogenesis
Knockout
CRISPR knockout of genes such as KLF15, VASN, or DCBLD1 in endothelial cells abolishes their negative regulatory function, leading to increased angiogenesis in tube formation and sprouting assays. This provides direct causal evidence for their role in GO:0016525.
Point Mutation
CRISPR point mutation knock-in can dissect specific residues required for anti-angiogenic activity, such as endocytosis motifs in DCBLD1 or phosphorylation sites in VEGFR-1. These models reveal mechanistic details of negative regulation.
Knock-in
Knock-in of fluorescent or epitope tags allows visualization of endogenous proteins and their localization during angiogenesis. Knock-in of disease-associated variants can model how mutations impair negative regulation of angiogenesis.
Overexpression
CRISPR-mediated overexpression of negative regulators such as soluble VEGFR-1 or KLF15 can suppress angiogenesis in vitro and in vivo, validating their therapeutic potential. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports negative regulation of angiogenesis Research
Researchers studying negative regulation of angiogenesis-related genes often need to determine whether a candidate gene is causally involved in suppressing vessel formation. EDITGENE provides CRISPR-based cell model services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of angiogenesis research.
Frequently Asked Questions About negative regulation of angiogenesis
What is negative regulation of angiogenesis GO:0016525?
It is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of angiogenesis.
What genes are involved in negative regulation of angiogenesis?
Key genes include VEGFR1 (sFlt-1), KLF15, VASN, NOTCH1, DCBLD1, SDC4, and NFE2L2 (Nrf2).
How does soluble VEGFR-1 inhibit angiogenesis?
Soluble VEGFR-1 sequesters VEGF and PlGF, preventing them from activating VEGFR-2 on endothelial cells.
What is the role of Notch1 in negative regulation of angiogenesis?
Notch1 signaling downstream of KLF15/VASN suppresses endothelial sprouting and inhibits angiogenesis.
How does DCBLD1 modulate angiogenesis?
DCBLD1 regulates VEGFR-2 endocytosis, thereby controlling the availability of the receptor for pro-angiogenic signaling.
What diseases are associated with impaired negative regulation of angiogenesis?
Cancer, diabetic foot ulcers, and triple negative breast cancer are associated with dysregulated negative regulation of angiogenesis.
How can CRISPR be used to study negative regulation of angiogenesis?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of candidate genes in endothelial cells.
What assays measure negative regulation of angiogenesis?
Tube formation, sprouting, Matrigel plug, and corneal micropocket assays are commonly used.
What is the role of epigenetic regulation in negative regulation of angiogenesis?
Histone deacetylases regulate Nrf2-mediated angiogenesis, affecting diabetic wound healing.
How do catecholamines affect angiogenesis in wound healing?
Catecholamines modulate angiogenesis during cutaneous wound healing, providing neuroendocrine control.
Conclusion
Negative regulation of angiogenesis (GO:0016525) is a critical biological process that maintains vascular homeostasis by counteracting pro-angiogenic signals. Key molecular players include soluble VEGFR-1, the KLF15/VASN/Notch1 axis, DCBLD1, and epigenetic regulators such as HDACs. Dysregulation of this process contributes to cancer, diabetic complications, and impaired wound healing. CRISPR-based cell models are indispensable for dissecting the causal roles of these genes and for developing targeted therapies.
References
- 1. Failla CM et al.. 2018. Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1.. Int J Mol Sci 19(5) PMID: 29702562
- 2. Chakroborty D et al.. 2020. Catecholamines in the regulation of angiogenesis in cutaneous wound healing.. FASEB J 34(11):14093-14102 PMID: 32949437
- 3. Fidler IJ. 2001. Regulation of neoplastic angiogenesis.. J Natl Cancer Inst Monogr PMID: 11158201
- 4. Zhang J et al.. 2025. Endothelial KLF15/VASN Axis Inhibits Angiogenesis via Activation of Notch1 Signaling.. Circ Res 136(12):1595-1609 PMID: 40297901
- 5. Goel S et al.. 2011. Normalization of the vasculature for treatment of cancer and other diseases.. Physiol Rev 91(3):1071-121 PMID: 21742796
- 6. Onyeisi JOS et al.. 2025. Role of syndecan-4 in angiogenesis and vasculogenic mimicry in triple negative breast cancer cells.. Matrix Biol 136:127-133 PMID: 39938698
- 7. Harithpriya K et al.. 2024. Epigenetic regulation of Nrf2-Mediated angiogenesis in diabetic foot ulcer progression: Role of histone deacetylases.. Arch Biochem Biophys 760:110133 PMID: 39181383
- 8. Feng Q et al.. 2025. DCBLD1 Modulates Angiogenesis by Regulation of the VEGFR-2 Endocytosis in Endothelial Cells.. Arterioscler Thromb Vasc Biol 45(2):198-217 PMID: 39665138
